RxDoctor Payments Data

Sushanth Reddy, MD

Surgery · Birmingham, ALNPI 1588815823

Payments from drug & device makers

$5,545in general payments, 2019–2025

Across 41 payments — averaging $135.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Medtronic$1K
  • Intera Oncology, Inc$390
  • AbbVie$381
  • Johnson & Johnson$365
  • Sirtex Medical Inc$175
  • plus $224 from 3 others

What the payments were for

  • Travel & lodging$1,96435%
  • Food & beverage$2,08138%
  • Education$1,50027%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical12$2,959
Medtronic(2 entities)12$1,051
Intera Oncology, Inc2$390
AbbVie3$381
Johnson & Johnson4$365
Sirtex Medical Inc2$175
Advanced Accelerator Applications1$124
UCB, Inc.4$87
Lundbeck LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,545 in reported general payments places this provider in the 70th percentile of 382 surgery providers in Alabama.

See all surgery providers in Alabama

Medicare billing

Part B allowed, 2024
$87,951
Medicare patients
111
Services billed
262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase28$45,898
Oxycodone Hcl27$190
Diazepam11$7

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$381$45,89828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 382 surgery providers in Alabama.

Other surgery in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →